Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think it is a completely relevant question. IMHO, if the overseas shipment of product that was supposed to occur in March did actually occur, a microcap the likes of VDRM would want to scream that from the rooftops. Why would they sit on that information only to be buried in a 10Q? I think we all know the answer to that...there's no announcement because it didn't happen; and such failure to follow through on announcements is typical. I'd like to give the DOC a pass by stating that it hasn't happened yet, but his poor track record persuades me otherwise. I wish I could state that this stock owes me nothing but I haven't been smart trading this thing...so still holding and waiting for the DOC to produce.
Not it is not. If it is taking place this March, you must wait for the 1Q-24 to find out. See, some people that has not clue like drama and spend their entire lives on such. Wait for 1Q-24 and if it is not there the info you want, then YES, you can chant all about it!!!
What happened to the overseas shipment of product that was announced taking place in March that everyone bragged about? Same old song and dance, big announcements then frekkin nothing. Nupelo big announcement, fancy website, then nothing. The list of BS goes on and on and the pumpers still pump, the so-called experts still spew their BS, and occasionally Sloppy brags about buying another bottle of Ulta like that means anything to anyone. Getting off at the next exit as this stock owes me nothing. I have no doubt that the nonsense here will continue with the same cast of characters with the same line of nonsense and bullshit. PPS still holding....What a crock of crap. Typical though. Have fun! Bye.
Thanks. Did the little birdie whisper anything else in your ear that you may want to share 😀
Hopefully, removal of Pink Limited sign is the only restraint to news release. Otherwise, it will mean that proclamations of On Schedule for overseas shipments in March were not realized (like other things in the past).
Hearing attorney letter will be filed this week.
Hahahahahahaha BWAAAHH!!! I have not idea that I was doing something extra in here other than just interacting with others. Isn’t this type of social media platform for such only? You are extremely confused kid to even believe someone else might be in the thought that their posts can do a movement, specially in a platform like iHub. Look at you big shot, so the friend of your friend is the IR!!! WOW so you know insiders now!!! WOW you should feel high now. Chuckles, so infantile
I think you are about or you are already getting into an anxiety attack at the moment. Your replies don’t make sense mate. Are you okay? Who the hell is Rich? I don’t give a f… You got an imaginary RI friend
So, you clowns really think you are doing something, REALLY? Keep whining, that will do it and encourage others.
Just wondering: How many talk to IR, Rich? I talk or text with him probably 50x per week... Nothing inside, but I have a very good idea of what is going on. I've known Rich for about 8 years now.
But, keep whining, that will get it done! I see the WHINING and wonder why the WHINERS are invested here>>>?
Great "ENGRISH" on the underlined portion..
Patience!!! Been many years people keep saying the same Bs with patience in here. This CEO needs to be gone. Appoint someone else more capable
The funniest of all is the part HE BELIEVES to know the way or what think as well. He is so silly Lmaoo. I turned red of so much laugh when I saw his post. The easy way out!!! LMFAO
Well said!!! If he didnt get it, definitely his situation is mental
That's 4 share holders YOU don't even count
"Getting along" in your books is posting only positive rinse and repeat pump lines and no questioning or critiquing.
GTFOH 🤡
Sit back, relax...how many years have been saying to have patience? Better push the needle a little on that broken record...its starting to skip. Are you a shill for the DOC? Nevermind, don't care. You are irrelevant. IGNORE.
Tell him about your resume. That should win him over
Yup, just the constant low whine "of high heeled boys"...
Funny how so many think they know more of what's going on than they do. Then, they further think their comments are going to result in something, LIKE THE DR. IS READING THE BOARD. Do not like the Dr./what he is doing/the company, DON'T WHINE, JUST SELL!
So pathetic and lame! Just relax, STFU and have patience!
Then a couple weeks later the CPA found some old debt they like forgot about lol. Then it seemed like he issued shares to take care of it, but perhaps never actually paid it off
Anyone remember that?
Does anyone remember said they were debt free??? lol
Wow, I wasn't aware of such a simple solution. If not for your insightful post, I would never have known that that was an option. I have a solution for you which you may also find simple, yet insightful. This Board is for the exchange of information and opinions. If you don't like what someone is posting feel free to use the ignore button or F-off! Thanks and have a nice day!
EVERYTHING HERE IS MY OPINION!
I agree, but if he comes with silly fairytale on 1Q24 filings. Ouch…
Simple way out is for the real whiners, you love them, I believe you speak for yourself. Next, The only mess he is trying to straighten up, is the one that he caused in firsthand. Also, we all know what he has been going through: DUBAI and HOSPITAL deals = NADA. He has not landed any significant deal with nobody. Last supper: NUPELO!!! You have short time period memory, man. Also check the history of delayed fillings he has been going thru. No excuses, you are just trying to catch attention mate, defending a CEO like this will lead you to embarrassment. FACTS!!! Please erase that silly post of yours…
NOTE: Don’t ever forget, the money the Doc has used is from shareholders pockets!!! Nobody leaving at a loss… Smh
It is obvious that I was not clear enough. I only believe the CEO compensation clause regarding % of revenue for contracts he brings to company is egregious and indefensible. The others are not unreasonable. I fully support the incentive for reaching $1.00/share. However, giving himself 30% or 40% of revenue off of the top will be a massive drag on share price appreciation and potential to hit $1.00 with large contracts because new investors and speculators are going to have the advantage of being able to take that into account. The below analysis accepts original poster's premises (without contention) for this analysis. The second column depicts the potential impact of "CEO bonus" to the analysis. Hopefully, realized contracts will be all or mostly by sales people so that bonus clause is non-impactive. I still hope CEO comes through for all of us shareholders, in addition to just MASSIVELY for himself.
SELL YOUR STOCK IF YOU DON'T LIKE WHAT THE DR./CEO IS DOING!!!! Simple solution!
I just love all the whiners, not knowing what Dr. Otiko has gone through and the $ amount he has put into company TO STRAIGHTEN UP THE MESS!!
Simple solution is to sell if you don't like a direction a company takes!
Agree on all points. Otiko's compensation package is obscene. The only way I can make piece with it is that he must believe that he will be significantly growing the revenues. If he grows the revenues, the PPS rises. If the PPS gets anything close to Rainmaker's calculations, we will all be happy and retired and the next generation of shareholders can worry about Otiko.
100% excessive. If he felt he deserved so much why not take it private.
And remember folks, we have $1M in accounts receivables sitting uncollected for QUARTERS on end….
Like all the previous ones?
I don’t know what else to think with this CEO. He can’t set up any deals with nobody. I am telling you, ViaDerma issue is always has been the CEO
Assume Contract brought to company by CEO
Contract _ CEO _ VDRM
Value _ Bonus _ Revenue
Per Yr _ Per Yr _ Per Yr
$1M __ $0.3M _ $0.7M
$2M __ $0.8M _ $1.2M
$5M __ $2.0M _ $3.0M
$10M _ $4.0M _ $6.0M
$20M _ $8.0M _ $12.0M
The above is based on CEO performance clause and does not include his $0.1M salary and 20M share incentive each year he is CEO or one-time bonus of another 20M shares for $1.00/share. In total, I call that EXCESSIVELY STEEP price to pay as a shareholder for doing his job.
$.01172 When it does! The Dr. has been underfunded, has been working against some dirty former players in VDRM and he is getting it back in order. Financials are in and it all takes time! Viaderma does not have the resources of say a lly or pfe...
New products and new avenues for Vitastem will be very exciting.
To all the naysayers and antis, don't believe me, I don't give a F!
There is no other company like ViaDerma FACT
Again....blabbering nonsense that makes ZERO sense. ANYTHING is possible with ANY ticker. SMFH.....
The fact is anything is possible at this point
There are two likely big drags on your analysis potential realization and that is the CEO and the CEO. Infuriatingly, in all of these years and his"proclamations", he has yet to show that he can land any large contracts, that actually come to fruition. I am hoping that maybe he is constrained from announcing the actual overseas shipping start, due to the Yield sign, but I have not been able to confirm that. Separately, the CEO is again the big drawback, if he lands the contracts, by the embarrassing, beyond egregious contract clause (shown below) that he gave to himself.on October 1, 2022. We, the shareholders, need the company to land contracts, but not by the CEO, due to that ridiculous, undeserved clause. In any event, still hoping he somehow becomes professional and effective and makes us shareholders a great deal of money.
"In addition, CEO shall be entitled to a bonus of 30% of any revenue generated from contracts he brings into the company for the first
$1,000,000 in any fiscal year, or a bonus of 40% of any revenue generated from contract he brings into the company
over $2,000,000 in any fiscal year."
.50 cents per share you say? i think you are correct. simply break it down
50 states at 5k each is 250k per month = 3 million annual revenue
300k units per country in only 6 countries =1.8 million units at 50.00 per unit(its much more than that) = 90 million
that's 93 million divide by 1.25 billion shares =.0744 per share then put a 10x multiplier (should be 25% in this industry)
and there you have .744 cents per share value.
DOES NOT COUNT ANY NEW COUNTRES OR NUPELO AR ANYTHING ELSE IN THE PIPELINE
Never.....unless it reverse splits down the road ..
DB, let me know when it'll hit $.50; I'd like to retire soon.
$.01172 VDRM is coming together! It WILL go much higher and my only worry is someone taking it out @ too low a price. On its own, I can see $.50, YES FITTY CENTS! Don't think so? I don't give a F!
Too many know nutt'ns on this....
More like 7 years of dilution and no execution
Seven yrs. of hard work & waiting is behind us
I am on the positive side I use the product
That’s true. This company unlike many others out there has potential and good-real products. I have always had said it: VIADERMA ISSUE IS MANAGEMENT. Nothing else
It’s possible but the question is: Is there really going to be any news? I got the feeling Otiko will sink his big head for a long, long time in his mummy basement. Fillings? Sure, I won’t be surprised if I see attorney letter this month but beyond pinkeye current, Naah, a gamble.
SO much potential. That’s why it’s so damn frustrating lol
I Like the fact nobody was selling at the 8s and very few at 9s. Have a small position not as big as couple years ago. All good, hope everyone has a good weekend
Followers
|
619
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
74597
|
Created
|
10/27/08
|
Type
|
Free
|
Moderators |
ViaDerma's proprietary transdermal delivery system allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy.
The technology allows transfer of chemicals through the stratum corneum (outer layer of skin) with a diffusion constant which is 10,000 times higher than the diffusion constant which characterizes water movement through the stratum corneum.
This enables ViaDerma to pair almost any active ingredient with the technology and provide rapid transport of the medicine right to the site of action.
The first product is a broad spectrum tetracycline-based topical antibiotic is the only antibiotic in the world that kills bacteria both a physical and a chemical mechanism. All known antibiotics (other than ours) primarily use only a chemical mechanism of kill. The physical mechanism of kill is a key feature of what we call Rapid Active Ingredient Delivery System (RAIDS). One result of RAIDS is that tetracycline is carried in higher concentrations, more quickly, to and through the cell walls, where the tetracycline can become more effective than if conventional antibiotics were used. Conventional antibiotics require more time (usually prescribed for 5 to 7 days for best results), whereas our tetracycline-based products usually produce desirable results in 24 hours (or less) because of the RAIDS effect.
A second important result of RAIDS is that the topical antibiotic kills all harmful Gram positive and Gram negative bacteria that have been available for testing. We believe this is the world’s strongest broad-spectrum topical antibiotic available.
The potential commercial impact is immense. Drug developers believe it takes much longer for bacteria to develop drug resistance to a physical kill mechanism. This is because it is relatively easy for bacteria to change their response to a chemical threat, but it takes numerous generations for bacteria to grow a new kind of cell wall structure to respond to a physical threat.
Our novel approach to overcome drug resistance of antibiotics is designed to sustain the effectiveness of antibiotics and other topical drugs for many years. This gives new topical drug products a longer useful lifetime and therefore more commercial value. This technology, when licensed to larger pharmaceutical companies, may provide stronger incentive for the discovery and development of new antimicrobial drugs. In recent years, the dearth of new antibiotics has been largely due to the uncertain new-drug commercial lifetime which is diminished when bacteria develop immunity to that drug.
In addition the technology can be licensed to other companies to convert existing oral drugs to transdermal medications extending the profitably of the existing drug.
We are developing products in the following fields of use;
Treats all types of bacteria including MRSA, VRE and other flesh eating bacteria. Fights drug resistant bacteria. $6B/year global market.
Onychomycosis, a fungal infection of the toenails, is a major health problem. It is estimated that there are in excess of 40 million sufferers with this condition in the USA. It is a problem throughout the world. A recent European study showed that the prevalence of Onychomycosis may be as high as 26.9%. Fungal resistance can occur when the oral antifungal agents are used on a long-term basis. Topically applied antifungal drugs may work somewhat better adjunctive to surgical removal or chemical dissolution of the nail plate. Yet, this often ineffective and traumatic procedure leaves the subject without a nail for months at risk for re-infection. Given the limitations of current treatment options in this $3B market, there is a great need for a simple, nontoxic and effective alternative treatment. Estimated Global prevalence rate: 140 million.
Treats symptoms of Influenza which is a$4B/ year global market: Common
Diabetic foot wounds.
Per 3/8/18 PR: ViaDerma’s technology is currently being used in Elixr Cannabis products; Topical Balm, Topical Serum and Topical Spray. Sales have begun in Canada.
Per 12/7/17 PR: The Company has signed an MOU and will start production of its Patent Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent #62466209, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent # 62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinary uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments.
Per 1/23/18 PR: The Company has also a licensing and distribution agreement in place with its Canadian partners to produce a CBD Topical Serum, which has a 92% absorption rate powered by ViaDerma's Patent Pending Dual Carrier Technology. The CBD and Terpene profile (enriched with specific essential oils and vitamins C, and D) is crafted to alleviate Chronic Dry Skin, Psoriasis, Eczema, Rosacea, and many other skin conditions. The serum has anti-inflammatory, anti-bacterial, and chronic pain relief properties that are absorbed by the skin and provide overall healing benefits. Sales are expected to begin in the first quarter of 2018 and are projected to generate approximately $2 million annual revenues.
The Patented Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2018.
CBD is a compound found in the Cannabis family of plants such as hemp. CBD is combined into our topical body care products like Elixr's Topical Balm, Serum, and Spray.
CBD is an antioxidant. Antioxidants protect our skin from damaging exposure to smoke, UV rays, and environmental pollutants. Cannabinoid receptors are located all throughout the skin, Topical CBD products interact with those receptors resulting homeostasis and healing. Studies show that CBD can help treat an array of skin conditions such as eczema, psoriasis, rosacea, and acne.
"What is Intellectual Property?" - A Publication by the World Intellectual Property Organization -
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |